Core Viewpoint - Haohai Biological Technology (06826) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 24,000 shares at a total cost of HKD 650,500 [1] - The buyback price ranges from HKD 27.02 to HKD 27.22 per share [1]

智通财经APP讯，昊海生物科技(06826)发布公告，于2025年10月27日该公司斥资65.05万港元回购2.4万 股，回购价格为每股27.02-27.22港元。 ...

| 2. 股份分類 | | 普通股 | 股份類別 A | | | 於香港聯交所上市 | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | | | 說明 | | A 股（上海證券交易所科創板，股份代號：688366） | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | | 已發行股份總數 | | | | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | | | | 於下列日期開始時的結存(註1) | | 2025年9月30日 | | 190,203,760 | | 3,848,095 | | | 194,051,855 | | 1). 其他 (請註明) | | | | 0 | % | 0 | | | | | 不適用 | | | | | | ...

Core Points - The company ensures the authenticity, accuracy, and completeness of the quarterly report, with all board members and senior management bearing legal responsibility for any misstatements or omissions [2][3][4] Financial Data - The financial statements for the third quarter are unaudited, covering a three-month period from the beginning to the end of the quarter [3][7] - The company has reported non-recurring gains and losses, which are applicable and need to be explained if they are significant [4][6] - The company has not experienced any changes in the number of shareholders or significant changes in the top ten shareholders due to stock lending activities [5][6] Shareholder Information - As of September 30, 2025, the company holds 3,848,095 shares in its repurchase account, representing 1.65% of total shares [5][6] Other Information - The company has not provided any additional important information regarding its operational performance during the reporting period [6][8]

格隆汇10月24日丨昊海生物科技(06826.HK)公布2025年第三季度报告。营业收入约为人民币5.95亿元， 同比下降11.29%。归属于上市公司股东的净利润为9358.21万元，同比下降11.39%。基本每股收益为 0.40元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 上海昊海生物科技股份有限公司 主席 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2025年第三季度報告 本公告乃上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)及13.10B條以及香港 法例第571章證券及期貨條例第XIVA部刊發，旨在向本公司股東及公眾人士提供 本公司最新的財務資料。 茲載列本公司同時在上海證券交易所網站發佈的、截至2025年9月30日止三個月 及九個月之本集團未經審計業績（「第三季度報告」）。第三季度報告所載財務數據 乃根據中國企業會計準則編製，且未經審計。以下所載第三季度報告以中英文版 本編製。有任何歧義，概以第三季度報告中文版本為準。 本 ...

Core Insights - Haohai Biological Technology (688366.SH) reported a total operating revenue of 1.899 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 8.47% [1] - The net profit attributable to shareholders of the parent company was 305 million yuan, down 10.63% year-on-year [1] - The basic earnings per share stood at 1.31 yuan [1]

Core Insights - Haohai Biological Technology (688366) reported a decline in revenue and net profit for the first three quarters of 2025, with revenue at 1.899 billion yuan, down 8.47% year-on-year, and net profit at 305 million yuan, down 10.63% year-on-year [1] Financial Performance - The company's revenue for the first three quarters was 1.899 billion yuan, reflecting an 8.47% decrease compared to the same period last year [1] - The net profit attributable to the company was 305 million yuan, which represents a 10.63% decline year-on-year [1] Factors Affecting Performance - The decline in sales revenue was attributed to insufficient domestic consumer demand, price competition, and tax rate adjustments [1]

Company Performance - Haohai Biological Technology reported Q3 performance with revenue of approximately 1.899 billion yuan, a year-on-year decrease of 8.47% [1] - The net profit attributable to shareholders was about 305 million yuan, down 10.63% year-on-year [1] - Basic earnings per share were 1.31 yuan, reflecting a decrease of 10.27% compared to the previous year [1] Market Context - As of the report, Haohai Biological Technology has a market capitalization of 11.7 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing deals totaling 80 billion US dollars this year [2] - Despite the hot secondary market for biopharmaceuticals, the primary market is experiencing a cooling in fundraising [2]

上海昊海生物科技股份有限公司 2025 年第三季度报告 证券代码：688366 证券简称：昊海生科 上海昊海生物科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海昊海生物科技股份有限公司 2025 年第三季度报告 | 加权平均净资产收益率 | 1.66 | 减少 | 个 0.19 | 5.39 | 减少 0.54 | 个百 | | --- | --- | --- | --- | --- | --- | --- | | （%） | | | 百分点 | | | 分点 | | 研发投入合计 | 50,698,539.50 | | -19.19 | 149,099,493.94 | | -20.75 | | 研发投入占营业收入的 | 8.53 | 减少 | 0.83 个 | 7.85 | 减少 1.22 | 个百 | | 比例（%） | | | 百分点 | | | 分点 | | | 本报告期末 | | | 上年度末 | 本报告期末比 上年度末增减 | | | | | | ...